Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philip G Penketh

Showing results (1-10 of 33) with videos related to

Pageof 4
Sort By:
Theory in Biosciences = Theorie in Den Biowissenschaften|January 1, 2022
Is DNA repair controlled by a biological logic circuit?Philip G Penketh
Molecular Cancer Therapeutics|November 9, 2005
Role of O6-alkylguanine-DNA alkyltransferase in the cytotoxic activity of cloretazineKimiko Ishiguro, Krishnamurthy Shyam, Philip G Penketh, et al.
Analytical Biochemistry|September 12, 2008
Development of an O(6)-alkylguanine-DNA alkyltransferase assay based on covalent transfer of the benzyl moiety from [benzene-3H]O(6)-benzylguanine to the proteinKimiko Ishiguro, Krishnamurthy Shyam, Philip G Penketh, et al.
Molecules (Basel, Switzerland)|January 9, 2021
Design Strategy for the EPR Tumor-Targeting of 1,2-Bis(sulfonyl)-1-alkylhydrazinesPhilip G Penketh, Hugh S Williamson, Raymond P Baumann, et al.
Biochemical Pharmacology|April 29, 2005
Differential inhibition of cellular glutathione reductase activity by isocyanates generated from the antitumor prodrugs Cloretazine and BCNUKevin P Rice, Philip G Penketh, Krishnamurthy Shyam, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 21, 2005
1,2-Bis(methylsulfonyl)-1-(2-chloroethyl)-2-[[1-(4-nitrophenyl)ethoxy]carbonyl]hydrazine: an anticancer agent targeting hypoxic cellsHelen A Seow, Philip G Penketh, Krishnamurthy Shyam, et al.
Journal of Medicinal Chemistry|January 15, 2013
Hypoxia-selective O6-alkylguanine-DNA alkyltransferase inhibitors: design, synthesis, and evaluation of 6-(benzyloxy)-2-(aryldiazenyl)-9H-purines as prodrugs of O6-benzylguanineRui Zhu, Raymond P Baumann, Philip G Penketh, et al.
Molecular Cancer Therapeutics|May 2, 2006
Mode of action of the chloroethylating and carbamoylating moieties of the prodrug cloretazineKimiko Ishiguro, Helen A Seow, Philip G Penketh, et al.
Oncology Research|January 18, 2006
The antineoplastic efficacy of the prodrug Cloretazine is produced by the synergistic interaction of carbamoylating and alkylating products of its activationRaymond P Baumann, Helen A Seow, Krishnamurthy Shyam, et al.
Radiation Research|October 31, 2008
Generation of oxygen deficiency in cell culture using a two-enzyme system to evaluate agents targeting hypoxic tumor cellsRaymond P Baumann, Philip G Penketh, Helen A Seow, et al.
Pageof 4

Showing results (1-10 of 33) with videos related to

Sort By:
Pageof 4
Theory in Biosciences = Theorie in Den Biowissenschaften|January 1, 2022
Is DNA repair controlled by a biological logic circuit?Philip G Penketh
Molecular Cancer Therapeutics|November 9, 2005
Role of O6-alkylguanine-DNA alkyltransferase in the cytotoxic activity of cloretazineKimiko Ishiguro, Krishnamurthy Shyam, Philip G Penketh, et al.
Analytical Biochemistry|September 12, 2008
Development of an O(6)-alkylguanine-DNA alkyltransferase assay based on covalent transfer of the benzyl moiety from [benzene-3H]O(6)-benzylguanine to the proteinKimiko Ishiguro, Krishnamurthy Shyam, Philip G Penketh, et al.
Molecules (Basel, Switzerland)|January 9, 2021
Design Strategy for the EPR Tumor-Targeting of 1,2-Bis(sulfonyl)-1-alkylhydrazinesPhilip G Penketh, Hugh S Williamson, Raymond P Baumann, et al.
Biochemical Pharmacology|April 29, 2005
Differential inhibition of cellular glutathione reductase activity by isocyanates generated from the antitumor prodrugs Cloretazine and BCNUKevin P Rice, Philip G Penketh, Krishnamurthy Shyam, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 21, 2005
1,2-Bis(methylsulfonyl)-1-(2-chloroethyl)-2-[[1-(4-nitrophenyl)ethoxy]carbonyl]hydrazine: an anticancer agent targeting hypoxic cellsHelen A Seow, Philip G Penketh, Krishnamurthy Shyam, et al.
Journal of Medicinal Chemistry|January 15, 2013
Hypoxia-selective O6-alkylguanine-DNA alkyltransferase inhibitors: design, synthesis, and evaluation of 6-(benzyloxy)-2-(aryldiazenyl)-9H-purines as prodrugs of O6-benzylguanineRui Zhu, Raymond P Baumann, Philip G Penketh, et al.
Molecular Cancer Therapeutics|May 2, 2006
Mode of action of the chloroethylating and carbamoylating moieties of the prodrug cloretazineKimiko Ishiguro, Helen A Seow, Philip G Penketh, et al.
Oncology Research|January 18, 2006
The antineoplastic efficacy of the prodrug Cloretazine is produced by the synergistic interaction of carbamoylating and alkylating products of its activationRaymond P Baumann, Helen A Seow, Krishnamurthy Shyam, et al.
Radiation Research|October 31, 2008
Generation of oxygen deficiency in cell culture using a two-enzyme system to evaluate agents targeting hypoxic tumor cellsRaymond P Baumann, Philip G Penketh, Helen A Seow, et al.
Pageof 4